Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Irinotecan 6Temozolomide 5Cyclophosphamide 5Vincristine 4Magnetic Resonance Spectroscopy 4Doxorubicin 4palbociclib 3X-Rays 3Phantoms, Imaging 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ganitumab 2eribulin 2cixutumumab 2cabozantinib 2abemaciclib 2Vemurafenib 2Specimen Handling 2Radiotherapy, Image-Guided 2Radiosurgery 2Peripheral Blood Stem Cell Transplantation 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2FANG vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Ewing × BAY 1895344 × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡